FDA Advisors Strongly Back New Alzheimer’s Drug, Despite Risks and Limitations
In a significant development for Alzheimer’s treatment, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee has unanimously endorsed the approval of Eli Lilly’s new Alzheimer’s drug, donanemab. The committee’s decision, made on June 10, 2024, comes after a